We recently had a chance to interview one of the portfolio managers for the Ranger Equity Bear ETF (NYSEMKT: HDGE), which is an actively managed short selling exchange-traded fund. It acts like a short selling hedge fund but with instant market liquidity features that an ETF structure provides. The ETF’s major short selling position in shares of International Business Machines Corp. (NYSE: IBM) was what really piqued our interest. Investors did well who decided to move out of IBM as Big Blue’s stock price has managed to fall by more than $11 per share since then. It turns out that the team here remains a short seller of IBM, and this is indirectly a bet against Warren Buffett.
The reason we are revisiting this is not just to offer a cheerleading session for a short seller, but because IBM is extremely important to the market. IBM is not just a DJIA component. It is the largest DJIA component by far because of its share price being so high and the DJIA being a price-weighted stock index rather than a market cap-weighted index. Another reason that IBM is of such interest to us on a slow August day is that it is one of the cheapest Warren Buffett stocks for value investors if you use the implied upside expected by Wall Street analysts. IBM has now hit a new 52-week low, but the consensus analyst price target implies something to the tune of 17%.
5 Best Safest Stocks To Buy Right Now: USmart Mobile Device Inc (UMDI)
USmart Mobile Device Inc., formerly ACL Semiconductors Inc., incorporated on September 17, 2002, the Company is engaged primarily in the business of distributing memory products under the Samsung brand name, which consists of Dynamic Random Access Memory (DRAM), Graphic Random Access Memory (Graphic RAM) and Flash for the Hong Kong and Southern China markets. The primary products the Company distributes and sells include Synchronous Dynamic Random Access Memory (SDRAMs), DDRs (DDR1, DDR2 and DDR3), Flash memory, Graphic RAM and LCD panels. In September 2012, the Company acquired Jussey Investments Limited.
Synchronous Dynamic Random Access Memory (SDRAMs), or mobile SDRAM, are used semiconductor memory component in computer peripherals, such as Hard Disk Drives (HDD), Digital Still Camera (DSC), Modems, ADSL Applications, DVD player, Set-top Box (STB), Digital TV, High Definition TV (HDTV) and Portable Multimedia Players (PMP). DDRs (DDR1, DDR2 and DDR3) are random access memory components that transfer data on both 0-1 and 1-0 clock transitions, theoretically yielding twice the data transfer rate of normal RAM or SDRAM.
Flash memory is a specialized type of memory component used to store user data and program code; it retains this information even when the power is off. Although Flash is predominantly used in mobile phones and tablets, it is commonly used in multi-media digital storage applications for products, such as moving picture experts group layer-3 audio (MP3) players, digital still camera DSC, Digital Voice Recorders, universal serial bus (USB) Disks and Flash Cards. Graphic RAM is a special purpose DDR (GDDR1, GDDR2, GDDR3, GDDR4) that is used in graphic products which require high-speed 3-dimensional calculation performance and a memory size to be used as data storage buffer for digital versatile disc (DVD) and computer game displays. LCD panels are a component in consumer electronics, such as LCD TVs, tablets, smartphones, notebooks, digital phone frames and por! table game consoles.
The Company competes with Toshiba, Hynix, Nanya, PSC, Promos, ISSI and ESMT.
Advisors' Opinion:- [By Peter Graham]
Last Friday, small cap stocks MedCAREERS Group Inc (OTCMKTS: MCGI), USmart Mobile Device Inc (OTCMKTS: UMDI) and Drinks Americas Holdings, Ltd (OTCMKTS: DKAM) were all over the place with the first two sinking 54% and 48.05%, respectively, while the last one rose 10.81%. It should be mentioned that all three small cap stocks have been the subject of paid promotions albeit none of these stocks have been over promoted. So where can investors and traders expect these stocks to head this week? Here is a quick look at what you might expect:
Top 5 International Stocks To Buy Right Now: Vanguard Large Cap Etf (VV)
Vanguard Large-Cap ETF, formerly known as Vanguard Large-Cap VIPERs, is an exchange-traded share class that seeks to track the investment performance of the Morgan Stanley Capital International (MSCI) US Prime Market 750 Index (Index). The Fund employs an indexing approach to provide exposure to predominantly large-cap companies in the United States, diversified across growth and value styles.
The Index represents the universe of predominantly large-capitalization companies in the United States equity market. Using full replication, the Fund invests in all of the Index stocks, holding each stock in approximately the same proportion as its weighting in the Index.
Advisors' Opinion:- [By Selena Maranjian]
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to add some large-cap stocks to your portfolio but don't have the time or expertise to hand-pick a few, the Vanguard Large-Cap ETF (NYSEMKT: VV ) could save you a lot of trouble. Instead of trying to figure out which large-cap stocks will perform best, you can use this ETF to invest in lots of them simultaneously.
The basics
ETFs often sport lower expense ratios than their mutual-fund cousins. This ETF, focused on large-cap stocks, sports a relatively low expense ratio -- an annual fee -- of 0.1%. It yields about 2%.
This ETF has performed reasonably, but it's also very young, with just a few years on the books. It underperformed the S&P 500 in 2008 and 2010, though it beat it substantially in 2007 and 2009. As with most investments, of course, we can't expect outstanding performances in every quarter or year. Investors with conviction need to wait for their holdings to deliver.
Top 5 International Stocks To Buy Right Now: Catalyst Pharmaceutical Partners Inc.(CPRX)
Catalyst Pharmaceutical Partners, Inc., a development-stage biopharmaceutical company, focuses on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. It is evaluating its lead product candidate, CPP-109, a GABA aminotransferase inhibitor candidate, which is under Phase II(b) clinical trial for the treatment of cocaine addiction, as well as focuses on evaluating CPP-109 for the treatment of other addictions and obsessive-compulsive disorders. The company is also developing CPP-115, a GABA aminotransferase inhibitor for various indications, including drug addiction, epilepsy, and for other selected central nervous disease indications. It has license agreements with Brookhaven Science Associates, LLC on various patents and patent applications relating to the use of vigabatrin as a treatment for cocaine and other addictions, and obsessive-compulsive disorders; and with Northwestern University to commercialize GABA aminotransferase inhibitors worldwide, as well as a definitive clinical trial agreement with the National Institute on Drug Abuse to jointly conduct a U.S. Phase II(b) clinical trial evaluating CPP-109 for the treatment of cocaine addiction. Catalyst Pharmaceutical Partners, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Advisors' Opinion:- [By John Udovich]
While the Twitter IPO has been grabing everyone�� attention, biotech IPOs continue to dominate both biotech and IPO news with Karyopharm Therapeutics Inc (NASDAQ: KPTI) going public yesterday and�Relypsa (NASDAQ: RLYP), TetraLogic Pharmaceuticals (NASDAQ: TLOG), Vital Therapies (NASDAQ: VTL) and Xencor (NASDAQ: XNCR) filing to go public in the near future�(despite the sector producing some�ugly charts�for the month of October) plus�another small cap called TNI BioTech (OTCMKTS: TNIB) has also been producing a steady flow of news:
Karyopharm Therapeutics Debuts. Yesterday, small cap Karyopharm Therapeutics, which is working on a drug that aids the body�� natural tumor-suppressing proteins,�debuted at the top of�its range to raise $109 million in an upsized�offering of 6.8 million shares at $16 apiece with shares closing at $16.81. It should be noted that Karyopharm Therapeutics��lead drug candidate (Selinexor) is in early-stage clinical trials�and the company lost�lost nearly $12.5 million on revenue of $366,000 during the first six months of this year. Biotech IPOs by Region. On an interesting note, Luke Timmerman, the National Biotech Editor of Xconomy, has written a�good�article tracking biotech or life sciences IPOs by region. By his count, Boston is home to eight of the 45 (18%) of the life sciences IPOs this year (its companies have also�raised the most money - about $770 million)�plus�the New York/northern New Jersey region is also home to�eight. San Diego�came in third with six IPOs followed by San Francisco with five while only five of the 45 biotech IPOs�came from outside the�US (Three from Israel and two from Europe). However, the above figures may change as by his account, there are 15 additional biotech companies in line to go public. More Biotechs Set IPO Terms. The small cap biotech space is about to be joined by a few new additions as a couple of biotechs file to go public�over the past�week or so: Relypsa, which is d - [By Paul Ausick]
Stocks on the move: Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX) is up about 40% at $1.98 after its firdapse drug treatment for certain kinds of muscle weakness was designated a breakthrough therapy by the FDA. Food maker Dean Foods Inc. (NYSE: DF) held a 1-for-2 reverse stock split this morning and the shares are up about 95%, as might be expected.
- [By Roberto Pedone]
One under-$10 biopharmaceutical player that's starting to move within range of triggering a big breakout trade is Catalyst Pharmaceutical Partners (CPRX), which is focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. This stock has been on fire so far in 2013, with shares up a whopping 364%.
If you take a look at the chart for Catalyst Pharmaceutical Partners, you'll notice that this stock has been uptrending strong for the last month, with shares soaring higher from its low of $1.29 to its intraday high of $2.09 a share. During that uptrend, shares of CPRX have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed share of CPRX within range of triggering a big breakout trade.
Traders should now look for long-biased trades in CPRX if it manages to break out above its 50-day moving average of $2.11 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average volume of 2.21 million shares. If that breakout triggers soon, then CPRX will set up to re-test or possibly take out its next major overhead resistance levels at $2.87 to $3 a share. Any high-volume move above those levels will then give CPRX a chance to re-test its 52-week high at $3.65 a share.
Traders can look to buy CPRX off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $1.65 to $1.63 a share. One can also buy CPRX off strength once it starts to take out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Top 5 International Stocks To Buy Right Now: TGC Industries Inc.(TGE)
TGC Industries, Inc. provides geophysical services for clients in the oil and gas business in the United States and Canada. It conducts three-D surveys and seismic data acquisition services primarily to onshore oil and natural gas exploration and development companies for use in the onshore drilling and production of oil and natural gas. The company also owns a data bank that contains gravity data and magnetic data from oil and natural gas producing areas located in the United States. It operates 8 seismic crews in the lower 48 states in the United States, as well as 2 crews in Canada. The company was formerly known as Tidelands Geophysical Co., Inc. and changed its name to TGC Industries, Inc. in July 1986. TGC Industries, Inc. was founded in 1967 and is headquartered in Plano, Texas.
Advisors' Opinion:- [By Roberto Pedone]
TGC Industries (TGE) provides geophysical services to companies in the oil and gas industry in the U.S. and Canada. This stock closed up 1.8% to $3.86 in Tuesday's trading session.
Tuesday's Range: $3.76-$3.89
52-Week Range: $3.69-$8.53
Tuesday's Volume: 382,000
Three-Month Average Volume: 114,667From a technical perspective, TGE jumped modestly higher here right above some near-term support at $3.69 with above-average volume flows. This stock recently formed a double bottom chart pattern at $3.72 to $3.69. Following that bottom, shares of TGE have now started to spike higher and it's quickly moving within range of triggering a big breakout trade. That trade will hit if TGE manages to take out some key near-term overhead resistance levels at $3.95 to $4 with high volume.
Traders should now look for long-biased trades in TGE as long as it's trending above those double bottom support levels and then once it sustains a move or close above those breakout levels with volume that hits near or above 114,667 shares. If that breakout triggers soon, then TGE will set up to re-test or possibly take out its next major overhead resistance levels at $4.25 to its 50-day moving average of $4.52, or even $4.75 to $5.
No comments:
Post a Comment